Evidence map›Paper›PMID 41155381›Full record

ArticleInternational journal of molecular sciences2025

Analysis of Selected Serum Cytokines to Evaluate the Early Efficacy of Benralizumab, Dupilumab, and Mepolizumab in Severe Eosinophilic Asthma Treatment.

Aleksandra Niemiec-Górska, Łukasz Labus, Sylwia Mielcarska, Joanna Glück, Zenon Czuba, Marcin Cyrnek, Olga Branicka, Barbara Rymarczyk, Radosław Gawlik

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Aleksandra Niemiec-GórskaChair and Department of Internal Medicine, Allergology and Clinical Immunology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, Medyków 14 Street, 40-752 Katowice, Poland.ORCID 0000-0001-8644-4048
Łukasz LabusDepartment of Lung Diseases and Tuberculosis, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, 40-752 Katowice, Poland.
Sylwia MielcarskaDoctoral School, Medical University of Silesia, 40-752 Katowice, Poland.ORCID 0000-0003-4228-9343
Joanna GlückChair and Department of Internal Medicine, Allergology and Clinical Immunology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, Medyków 14 Street, 40-752 Katowice, Poland.ORCID 0000-0001-6339-9053
Zenon CzubaChair and Department of Microbiology and Immunology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, 40-752 Katowice, Poland.ORCID 0000-0001-8216-4495
Marcin CyrnekChair and Department of Internal Medicine and Clinical Pharmacology, Faculty of Medical Sciences in Katowice, Medical University of Silesia, 40-752 Katowice, Poland.
Olga BranickaChair and Department of Internal Medicine, Allergology and Clinical Immunology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, Medyków 14 Street, 40-752 Katowice, Poland.ORCID 0000-0002-2464-8923
Barbara RymarczykChair and Department of Internal Medicine, Allergology and Clinical Immunology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, Medyków 14 Street, 40-752 Katowice, Poland.ORCID 0000-0002-9653-0801
Radosław GawlikChair and Department of Internal Medicine, Allergology and Clinical Immunology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, Medyków 14 Street, 40-752 Katowice, Poland.

Funding

Medical University of Silesia BNW-1-042/N/3/K
6 · The paper itself

Abstract

backgroundSevere asthma is a chronic, difficult-to-treat disorder that significantly affects quality of life, and oral glucocorticosteroids are usually required. Many patients suffering from severe asthma exhibit T2 inflammation and may benefit from biological treatment. This study aims to evaluate changes in cytokine concentrations during therapy with benralizumab, dupilumab, and mepolizumab in severe eosinophilic asthma. MATERIALS AND

methodsIn this prospective, single-center study, 39 patients with severe eosinophilic asthma received treatment with one of the above-mentioned biologics. Parameters, such as the cytokine profile (Human Th9/Th17/Th22 Luminex, Performance Assay 18-plex Fixed Panel, R&D Systems, Minneapolis, MN, USA) and additionally the Asthma Control Questionnaire (ACQ), mini-Asthma Quality of Life Questionnaire (mini-AQLQ), spirometry (FEV1, FEV/FVC), FeNO, and functional status, were assessed at baseline and after 3-4 months of therapy.

resultsThe biologic therapies demonstrated diverse effects on inflammatory biomarkers. Dupilumab showed the most pronounced decreases in CD40L, IL-6, and FeNO in comparison to other drugs. In turn, the greatest decrease in TNF-α concentration was observed in the group treated with mepolizumab.

conclusionChanges in cytokine concentrations highlight the heterogenous immunomodulatory mechanisms of biologics and support personalized strategies based on inflammatory profiles. However, the results should be interpreted with prudence, as the concentrations of cytokines in blood serum fluctuate and the study sample size is small.

Indexed as

Anti-Asthmatic AgentsAntibodies, Monoclonal, HumanizedAsthmaCytokinesAdultAgedBiomarkersFemaleHumansMaleMiddle AgedProspective StudiesQuality of LifeTreatment OutcomeAnti-Asthmatic AgentsAntibodies, Monoclonal, HumanizedbenralizumabBiomarkersCytokinesdupilumabmepolizumabbenralizumabdupilumabeosinophilic asthmamepolizumab cytokines

Identifiers

PMID41155381
PMCPMC12563325

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.